Pergolide compared with bromocriptine in Parkinson's disease: a multicenter, crossover, controlled study.
Identifieur interne : 004821 ( Ncbi/Merge ); précédent : 004820; suivant : 004822Pergolide compared with bromocriptine in Parkinson's disease: a multicenter, crossover, controlled study.
Auteurs : G. Pezzoli [Italie] ; E. Martignoni ; C. Pacchetti ; V A Angeleri ; P. Lamberti ; A. Muratorio ; U. Bonuccelli ; M. De Mari ; N. Foschi ; E. CossuttaSource :
- Movement disorders : official journal of the Movement Disorder Society [ 0885-3185 ] ; 1994.
English descriptors
- KwdEn :
- Aged, Bromocriptine (adverse effects), Bromocriptine (therapeutic use), Cross-Over Studies, Disability Evaluation, Dose-Response Relationship, Drug, Drug Therapy, Combination, Humans, Infant, Levodopa (adverse effects), Levodopa (therapeutic use), Male, Middle Aged, Neurologic Examination (drug effects), Parkinson Disease (drug therapy), Pergolide (adverse effects), Pergolide (therapeutic use), Single-Blind Method, Treatment Outcome.
- MESH :
- chemical , adverse effects : Bromocriptine, Levodopa, Pergolide.
- chemical , therapeutic use : Bromocriptine, Levodopa, Pergolide.
- drug effects : Neurologic Examination.
- drug therapy : Parkinson Disease.
- Aged, Cross-Over Studies, Disability Evaluation, Dose-Response Relationship, Drug, Drug Therapy, Combination, Humans, Infant, Male, Middle Aged, Single-Blind Method, Treatment Outcome.
Abstract
We compared the efficacy and safety of pergolide and bromocriptine in 57 patients with Parkinson's disease (PD) with a declining response to levodopa therapy in a single-blind, crossover study. Patients were placed randomly on the sequence bromocriptine-pergolide (12 + 12 weeks) or vice versa. Regular evaluations using the New York University Parkinson's Disease Scale were performed by a clinician blinded to treatment assignment. Patients' and clinicians' impressions also were recorded. The average daily dose of pergolide was 2.3 +/0- 0.8 mg, and that of bromocriptine was 24.2 +/- 8.4 mg. Significantly greater efficacy was demonstrated by both drugs as adjunctive therapy to levodopa compared with previous treatment of levodopa alone (pergolide, p = 0.0001; bromocriptine, p = 0.0005; Wilcoxon t test). Pergolide was more effective than bromocriptine in daily living scores (p = 0.020) and motor scores (p = 0.038). No difference in dyskinesias, dystonias, and psychosis was observed. Adverse events were more frequent in bromocriptine-treated patients. Most patients and physicians preferred pergolide to bromocriptine. Pergolide as adjunctive therapy to levodopa was more effective than bromocriptine in this short-term trial.
DOI: 10.1002/mds.870090409
PubMed: 7969210
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 004A82
- to stream PubMed, to step Curation: 004A82
- to stream PubMed, to step Checkpoint: 004A85
Links to Exploration step
pubmed:7969210Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Pergolide compared with bromocriptine in Parkinson's disease: a multicenter, crossover, controlled study.</title><author><name sortKey="Pezzoli, G" sort="Pezzoli, G" uniqKey="Pezzoli G" first="G" last="Pezzoli">G. Pezzoli</name><affiliation wicri:level="1"><nlm:affiliation>Institute of Clinical Neurology, University of Milan, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Institute of Clinical Neurology, University of Milan</wicri:regionArea><wicri:noRegion>University of Milan</wicri:noRegion></affiliation></author><author><name sortKey="Martignoni, E" sort="Martignoni, E" uniqKey="Martignoni E" first="E" last="Martignoni">E. Martignoni</name></author><author><name sortKey="Pacchetti, C" sort="Pacchetti, C" uniqKey="Pacchetti C" first="C" last="Pacchetti">C. Pacchetti</name></author><author><name sortKey="Angeleri, V A" sort="Angeleri, V A" uniqKey="Angeleri V" first="V A" last="Angeleri">V A Angeleri</name></author><author><name sortKey="Lamberti, P" sort="Lamberti, P" uniqKey="Lamberti P" first="P" last="Lamberti">P. Lamberti</name></author><author><name sortKey="Muratorio, A" sort="Muratorio, A" uniqKey="Muratorio A" first="A" last="Muratorio">A. Muratorio</name></author><author><name sortKey="Bonuccelli, U" sort="Bonuccelli, U" uniqKey="Bonuccelli U" first="U" last="Bonuccelli">U. Bonuccelli</name></author><author><name sortKey="De Mari, M" sort="De Mari, M" uniqKey="De Mari M" first="M" last="De Mari">M. De Mari</name></author><author><name sortKey="Foschi, N" sort="Foschi, N" uniqKey="Foschi N" first="N" last="Foschi">N. Foschi</name></author><author><name sortKey="Cossutta, E" sort="Cossutta, E" uniqKey="Cossutta E" first="E" last="Cossutta">E. Cossutta</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="1994">1994</date><idno type="RBID">pubmed:7969210</idno><idno type="pmid">7969210</idno><idno type="doi">10.1002/mds.870090409</idno><idno type="wicri:Area/PubMed/Corpus">004A82</idno><idno type="wicri:Area/PubMed/Curation">004A82</idno><idno type="wicri:Area/PubMed/Checkpoint">004A85</idno><idno type="wicri:Area/Ncbi/Merge">004821</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Pergolide compared with bromocriptine in Parkinson's disease: a multicenter, crossover, controlled study.</title><author><name sortKey="Pezzoli, G" sort="Pezzoli, G" uniqKey="Pezzoli G" first="G" last="Pezzoli">G. Pezzoli</name><affiliation wicri:level="1"><nlm:affiliation>Institute of Clinical Neurology, University of Milan, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Institute of Clinical Neurology, University of Milan</wicri:regionArea><wicri:noRegion>University of Milan</wicri:noRegion></affiliation></author><author><name sortKey="Martignoni, E" sort="Martignoni, E" uniqKey="Martignoni E" first="E" last="Martignoni">E. Martignoni</name></author><author><name sortKey="Pacchetti, C" sort="Pacchetti, C" uniqKey="Pacchetti C" first="C" last="Pacchetti">C. Pacchetti</name></author><author><name sortKey="Angeleri, V A" sort="Angeleri, V A" uniqKey="Angeleri V" first="V A" last="Angeleri">V A Angeleri</name></author><author><name sortKey="Lamberti, P" sort="Lamberti, P" uniqKey="Lamberti P" first="P" last="Lamberti">P. Lamberti</name></author><author><name sortKey="Muratorio, A" sort="Muratorio, A" uniqKey="Muratorio A" first="A" last="Muratorio">A. Muratorio</name></author><author><name sortKey="Bonuccelli, U" sort="Bonuccelli, U" uniqKey="Bonuccelli U" first="U" last="Bonuccelli">U. Bonuccelli</name></author><author><name sortKey="De Mari, M" sort="De Mari, M" uniqKey="De Mari M" first="M" last="De Mari">M. De Mari</name></author><author><name sortKey="Foschi, N" sort="Foschi, N" uniqKey="Foschi N" first="N" last="Foschi">N. Foschi</name></author><author><name sortKey="Cossutta, E" sort="Cossutta, E" uniqKey="Cossutta E" first="E" last="Cossutta">E. Cossutta</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="ISSN">0885-3185</idno><imprint><date when="1994" type="published">1994</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Bromocriptine (adverse effects)</term><term>Bromocriptine (therapeutic use)</term><term>Cross-Over Studies</term><term>Disability Evaluation</term><term>Dose-Response Relationship, Drug</term><term>Drug Therapy, Combination</term><term>Humans</term><term>Infant</term><term>Levodopa (adverse effects)</term><term>Levodopa (therapeutic use)</term><term>Male</term><term>Middle Aged</term><term>Neurologic Examination (drug effects)</term><term>Parkinson Disease (drug therapy)</term><term>Pergolide (adverse effects)</term><term>Pergolide (therapeutic use)</term><term>Single-Blind Method</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Bromocriptine</term><term>Levodopa</term><term>Pergolide</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Bromocriptine</term><term>Levodopa</term><term>Pergolide</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Neurologic Examination</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Cross-Over Studies</term><term>Disability Evaluation</term><term>Dose-Response Relationship, Drug</term><term>Drug Therapy, Combination</term><term>Humans</term><term>Infant</term><term>Male</term><term>Middle Aged</term><term>Single-Blind Method</term><term>Treatment Outcome</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">We compared the efficacy and safety of pergolide and bromocriptine in 57 patients with Parkinson's disease (PD) with a declining response to levodopa therapy in a single-blind, crossover study. Patients were placed randomly on the sequence bromocriptine-pergolide (12 + 12 weeks) or vice versa. Regular evaluations using the New York University Parkinson's Disease Scale were performed by a clinician blinded to treatment assignment. Patients' and clinicians' impressions also were recorded. The average daily dose of pergolide was 2.3 +/0- 0.8 mg, and that of bromocriptine was 24.2 +/- 8.4 mg. Significantly greater efficacy was demonstrated by both drugs as adjunctive therapy to levodopa compared with previous treatment of levodopa alone (pergolide, p = 0.0001; bromocriptine, p = 0.0005; Wilcoxon t test). Pergolide was more effective than bromocriptine in daily living scores (p = 0.020) and motor scores (p = 0.038). No difference in dyskinesias, dystonias, and psychosis was observed. Adverse events were more frequent in bromocriptine-treated patients. Most patients and physicians preferred pergolide to bromocriptine. Pergolide as adjunctive therapy to levodopa was more effective than bromocriptine in this short-term trial.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">7969210</PMID><DateCreated><Year>1994</Year><Month>12</Month><Day>14</Day></DateCreated><DateCompleted><Year>1994</Year><Month>12</Month><Day>14</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0885-3185</ISSN><JournalIssue CitedMedium="Print"><Volume>9</Volume><Issue>4</Issue><PubDate><Year>1994</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Movement disorders : official journal of the Movement Disorder Society</Title><ISOAbbreviation>Mov. Disord.</ISOAbbreviation></Journal><ArticleTitle>Pergolide compared with bromocriptine in Parkinson's disease: a multicenter, crossover, controlled study.</ArticleTitle><Pagination><MedlinePgn>431-6</MedlinePgn></Pagination><Abstract><AbstractText>We compared the efficacy and safety of pergolide and bromocriptine in 57 patients with Parkinson's disease (PD) with a declining response to levodopa therapy in a single-blind, crossover study. Patients were placed randomly on the sequence bromocriptine-pergolide (12 + 12 weeks) or vice versa. Regular evaluations using the New York University Parkinson's Disease Scale were performed by a clinician blinded to treatment assignment. Patients' and clinicians' impressions also were recorded. The average daily dose of pergolide was 2.3 +/0- 0.8 mg, and that of bromocriptine was 24.2 +/- 8.4 mg. Significantly greater efficacy was demonstrated by both drugs as adjunctive therapy to levodopa compared with previous treatment of levodopa alone (pergolide, p = 0.0001; bromocriptine, p = 0.0005; Wilcoxon t test). Pergolide was more effective than bromocriptine in daily living scores (p = 0.020) and motor scores (p = 0.038). No difference in dyskinesias, dystonias, and psychosis was observed. Adverse events were more frequent in bromocriptine-treated patients. Most patients and physicians preferred pergolide to bromocriptine. Pergolide as adjunctive therapy to levodopa was more effective than bromocriptine in this short-term trial.</AbstractText></Abstract><AuthorList CompleteYN="N"><Author ValidYN="Y"><LastName>Pezzoli</LastName><ForeName>G</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Institute of Clinical Neurology, University of Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martignoni</LastName><ForeName>E</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Pacchetti</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Angeleri</LastName><ForeName>V A</ForeName><Initials>VA</Initials></Author><Author ValidYN="Y"><LastName>Lamberti</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Muratorio</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Bonuccelli</LastName><ForeName>U</ForeName><Initials>U</Initials></Author><Author ValidYN="Y"><LastName>De Mari</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Foschi</LastName><ForeName>N</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Cossutta</LastName><ForeName>E</ForeName><Initials>E</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>UNITED STATES</Country><MedlineTA>Mov Disord</MedlineTA><NlmUniqueID>8610688</NlmUniqueID><ISSNLinking>0885-3185</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>24MJ822NZ9</RegistryNumber><NameOfSubstance UI="D010479">Pergolide</NameOfSubstance></Chemical><Chemical><RegistryNumber>3A64E3G5ZO</RegistryNumber><NameOfSubstance UI="D001971">Bromocriptine</NameOfSubstance></Chemical><Chemical><RegistryNumber>46627O600J</RegistryNumber><NameOfSubstance UI="D007980">Levodopa</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D001971">Bromocriptine</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D018592">Cross-Over Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004185">Disability Evaluation</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004305">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004359">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D007223">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D007980">Levodopa</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D009460">Neurologic Examination</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D010300">Parkinson Disease</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D010479">Pergolide</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016037">Single-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016896">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1994</Year><Month>7</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1994</Year><Month>7</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1994</Year><Month>7</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">7969210</ArticleId><ArticleId IdType="doi">10.1002/mds.870090409</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Italie</li></country></list><tree><noCountry><name sortKey="Angeleri, V A" sort="Angeleri, V A" uniqKey="Angeleri V" first="V A" last="Angeleri">V A Angeleri</name><name sortKey="Bonuccelli, U" sort="Bonuccelli, U" uniqKey="Bonuccelli U" first="U" last="Bonuccelli">U. Bonuccelli</name><name sortKey="Cossutta, E" sort="Cossutta, E" uniqKey="Cossutta E" first="E" last="Cossutta">E. Cossutta</name><name sortKey="De Mari, M" sort="De Mari, M" uniqKey="De Mari M" first="M" last="De Mari">M. De Mari</name><name sortKey="Foschi, N" sort="Foschi, N" uniqKey="Foschi N" first="N" last="Foschi">N. Foschi</name><name sortKey="Lamberti, P" sort="Lamberti, P" uniqKey="Lamberti P" first="P" last="Lamberti">P. Lamberti</name><name sortKey="Martignoni, E" sort="Martignoni, E" uniqKey="Martignoni E" first="E" last="Martignoni">E. Martignoni</name><name sortKey="Muratorio, A" sort="Muratorio, A" uniqKey="Muratorio A" first="A" last="Muratorio">A. Muratorio</name><name sortKey="Pacchetti, C" sort="Pacchetti, C" uniqKey="Pacchetti C" first="C" last="Pacchetti">C. Pacchetti</name></noCountry><country name="Italie"><noRegion><name sortKey="Pezzoli, G" sort="Pezzoli, G" uniqKey="Pezzoli G" first="G" last="Pezzoli">G. Pezzoli</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004821 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 004821 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Ncbi
|étape= Merge
|type= RBID
|clé= pubmed:7969210
|texte= Pergolide compared with bromocriptine in Parkinson's disease: a multicenter, crossover, controlled study.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:7969210" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |